Status:
RECRUITING
Precision Cancer Therapy in Rare Cancers
Lead Sponsor:
Oslo University Hospital
Collaborating Sponsors:
Helse Stavanger HF
University Hospital of North Norway
Conditions:
Rare Malignant Neoplasm
Eligibility:
All Genders
16-99 years
Phase:
PHASE2
Brief Summary
Some rare cancers are hard-to-treat and patients have a poor prognosis. It is known that some of these patients have targetable molecular alterations, and some benefit from targeted drugs. However in ...
Detailed Description
All patients will have the tumour cells diagnosed with a large genepanel, analyzing more than 500 genes on DNA / RNA level. Patients will be treated based on the molecular characteristics of the tumor...
Eligibility Criteria
Inclusion
- ECOG 0-2,
- identified biomarker,
- reasonable biochemistry
Exclusion
- ECOG 3-5
- serious other diseases
Key Trial Info
Start Date :
March 20 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2036
Estimated Enrollment :
96 Patients enrolled
Trial Details
Trial ID
NCT06119789
Start Date
March 20 2025
End Date
August 1 2036
Last Update
March 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oslo University Hospital
Oslo, Norway, 0310